Track CING and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Cingulate Inc
1901 West 47th Place, Kansas City, KS, United States, 66205
IPO
2021
Employees
14
Industry
Biotechnology
Sector
Healthcare
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20260+4
4
Analyst Ratings
3 analysts covering
Buy100%recommend buy
Buy
3
Hold
0
Sell
0